The value of (-7,-5)pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer

被引:34
作者
Bangma, CH
Wildhagen, MF
Yurdakul, G
Schröder, FH
Blijenberg, BG
机构
[1] Erasmus MC, Dept Urol, NL-3000 CA Rotterdam, Netherlands
[2] Erasmus MC, Dept Clin Chem, NL-3000 CA Rotterdam, Netherlands
关键词
PSA; prostate cancer; isoforms; kallikrein; grading; proPSA;
D O I
10.1111/j.1464-410X.2003.04733.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
To assess the value of the precursor form (-7,5pro) of prostate-specific antigen (PSA) and human kallikrein-2 (hK2) for detecting and grading prostate cancer, as better serum markers with improved specificity are needed in men with lower ranges of total (t)PSA. tPSA, free PSA (fPSA), the precursor (-7,5)proPSA and hK2 were measured in a subset of participants of the European Randomised Study of Screening of Prostate Cancer. In a pilot study, sera from 143 men biopsied but with no prostate cancer, 142 with BPH, and 146 with prostate cancer were analysed to determine the relative value of serum markers for differentiating between the groups. Then , in 141 men with prostate cancer who had a radical prostatectomy, these serum markers were related to the pathological grading to analyse their value as prognostic variables. Levels of (-7,5)proPSA, hK2 and fPSA could be used to distinguish between BPH and cancer, but proPSA and hK2, alone or combined, did not improve the specificity of fPSA for discriminating BPH and cancer. There was also no correlation between these serum markers and pathological tumour grade. The clinical effect of using (-7,5)proPSA or hK2 for detecting and grading prostate cancer remains limited.
引用
收藏
页码:720 / 724
页数:5
相关论文
共 21 条
  • [1] The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma
    Bangma, CH
    Kranse, R
    Blijenberg, PG
    Schroder, FH
    [J]. JOURNAL OF UROLOGY, 1997, 157 (02) : 544 - 547
  • [2] The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population
    Bangma, CH
    Rietbergen, JBW
    Kranse, R
    Blijenberg, BG
    Petterson, K
    Schroder, FH
    [J]. JOURNAL OF UROLOGY, 1997, 157 (06) : 2191 - 2196
  • [3] Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater
    Becker, C
    Piironen, T
    Pettersson, K
    Hugosson, J
    Lilja, H
    [J]. UROLOGY, 2000, 55 (05) : 694 - 699
  • [4] Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer
    Brawer, MK
    Cheli, CD
    Neaman, IE
    Goldblatt, J
    Smith, C
    Schwartz, MK
    Bruzek, DJ
    Morris, DL
    Sokoll, LJ
    Chan, DW
    Yeung, KK
    Partin, AW
    Allard, WJ
    [J]. JOURNAL OF UROLOGY, 2000, 163 (05) : 1476 - 1480
  • [5] Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: A novel prostate cancer marker
    Darson, MF
    Pacelli, A
    Roche, P
    Rittenhouse, HG
    Wolfert, RL
    Young, CYF
    Klee, GG
    Tindall, DJ
    Bostwick, DG
    [J]. UROLOGY, 1997, 49 (06) : 857 - 862
  • [6] Finlay JA, 2001, CLIN CHEM, V47, P1218
  • [7] Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml
    Haese, A
    Graefen, M
    Steuber, T
    Becker, C
    Pettersson, K
    Piironen, T
    Noldus, J
    Huland, H
    Lilja, H
    [J]. PROSTATE, 2001, 49 (02) : 101 - 109
  • [8] HOSEL W, 2002, ANTICANCER RES, V22, P529
  • [9] Krumholtz JS, 2002, UROLOGY, V60, P469, DOI 10.1016/S0090-4295(02)01875-7
  • [10] Kumar A, 2000, PROSTATE, V44, P248, DOI 10.1002/1097-0045(20000801)44:3<248::AID-PROS10>3.0.CO